Press Release

“The 20 abstracts to be presented at the upcoming AACR annual meeting underscore the breadth and potential of our innovative pipeline of oncology product candidates,” stated Reid Huber, Ph.D., Chief Scientific Officer, Incyte. “We are pleased to share these new data with the scientific community, and look forward to progressing these and the other clinical programs in our growing portfolio.”

Key abstracts, including Incyte-sponsored and independent investigator-sponsored studies, include:

Targeted therapies abstracts

Activity of the Selective FGFR 1, 2 and 3 Inhibitor INCB54828 in Genetically-Defined Models of Triple-Negative Breast Cancer (Abstract #531)

• Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 22

Preclinical Studies on Potential Therapeutic Combination Partners for the Potent and Selective PI3K Inhibitor INCB50465 in DLBCL (Abstract #143)

• Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 6

The Evaluation of INCB59872, an FAD-Directed Covalent Inhibitor of LSD1, in Preclinical Models of Ewing Sarcoma (Abstract #1162)

• Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 5

The Novel FGFR4-selective Inhibitor INCB62079 is Efficacious in Models of Hepatocellular Carcinoma Harboring FGF19 Amplification (Abstract #1234)

• Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 7

Mechanisms of Bromodomain and Extra-Terminal Motif Inhibitor (BETi) Sensitivity in Triple-Negative Breast Cancer (TNBC) (Abstract #1518)

• Monday, April 3, 2017, 8:00-12:00 p.m. EDT, Poster Section 20

Selective Inhibition of FGFR4 by INCB62079 is Efficacious in Models of FGF19- and FGFR4-Dependent Cancers (Abstract #2100)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33

Combination of Epigenetic Regulation with Targeted Therapies Significantly Enhances Anti-Tumor Effects in Hematologic Malignancy Models (Abstract #2032)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 4

Preliminary Results from a Phase 1/2 Study of INCB54828, a Highly Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients (pts) with Advanced Malignancies (Abstract #CT111)

• Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 33

INCB52793 JAK1 inhibitor synergizes with ATRA to inhibit expansion of AML (Abstract #3726)

• Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 29

The LSD1 Specific Inhibitor INCB59872 Enhances the Activity of Immune Checkpoint Blockade by Reshaping the Myeloid Compartment in the Syngeneic 4T1 Mouse Mammary Tumor Model (Abstract #4635)

• Tuesday, April 4, 2017, 1:00-5:00 p.m. EDT, Poster Section 27

The Selective Bromodomain Inhibitor, INCB54329 Targets both Cancer Cells and the Tumor Microenvironment in the KC Inflammatory Preclinical Model of Ductal Pancreatic Cancer (Abstract #5082)

• Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2

BET Inhibitors INCB54329 and INCB57643 Display Significant Activity in Androgen-Independent Prostate Cancer Models (Abstract #5080)

• Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2

Preclinical Characterization of the Potent and Selective BET Inhibitor INCB57643 in Models of Hematologic Malignancies (Abstract #5071)

• Wednesday, April 5, 2017, 8:00-12:00 p.m. EDT, Poster Section 2

Immuno-oncology abstracts

Inhibition of IDO1 with Epacadostat Enhances Anti-Tumor Efficacy of PD-1 Blockade in a Syngeneic Glioblastoma (GBM) Model (Abstract #572)

• Sunday, April 2, 2017, 1:00-5:00 p.m. EDT, Poster Section 25

Agonist Antibodies Targeting OX40 and GITR Enhance the Activity of the IDO1-Selective Inhibitor Epacadostat in Preclinical Models (Abstract #2618)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 25

INCAGN1876, a Unique GITR Agonist Antibody that Facilitates GITR Oligomerization (Abstract #3643)

• Tuesday, April 4, 2017, 8:00-12:00 p.m. EDT, Poster Section 26

INCAGN1949, an Anti-OX40 Antibody with an Optimal Agonistic Profile, with the Ability to Selectively Deplete Intratumoral Regulatory T Cells in a Range of Tumor Indications (Abstract #4703)

• Tuesday, April 4, 2017, 1:00-5:00 p.m. EDT, Poster Section 30

Trials-in-progress abstracts

Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB54828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement (Abstract #CT057)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33

Phase 2, Open-label, Multicenter Study of the Efficacy and Safety of INCB54828 for Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Alterations (Abstract #CT059)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33

Phase 2, Open-label, Multicenter Study of the Efficacy and Safety of INCB54828 in Patients with Advanced, Metastatic, or Surgically Unresectable Cholangiocarcinoma (CCA) With Inadequate Response to Prior Therapy (Abstract #CT063)

• Monday, April 3, 2017, 1:00-5:00 p.m. EDT, Poster Section 33

Full session details and data presentations at the AACR 2017 can be found here.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data regarding the Company’s development portfolio and the potential effectiveness of such portfolio, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including the Form 10-K for the year ending December 31, 2016. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005612/en/

Source: Incyte Corporation

Incyte Corporation
Media
Catalina Loveman, +1 302-498-6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302-498-5914
mbooth@incyte.com